Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for CNS Embryonal Tumors

    Staging of Medulloblastoma

    Historically, staging was based on an intraoperative evaluation of both the size and extent of the tumor, coupled with postoperative neuroimaging of the brain and spine and cytological evaluation of cerebrospinal fluid (CSF) (the Chang system). Intraoperative evaluation of the extent of the tumor has been supplanted by neuraxis imaging prior to diagnosis and postoperative imaging to determine amount of primary site residual disease. The following tests and procedures are now used for staging:

    Recommended Related to Cancer

    General Information About Colon Cancer

    Cancer of the colon is a highly treatable and often curable disease when localized to the bowel. Surgery is the primary form of treatment and results in cure in approximately 50% of the patients. Recurrence following surgery is a major problem and is often the ultimate cause of death. Incidence and Mortality Note: Estimated new cases and deaths from colon cancer in the United States in 2014:[1] New cases: 96,830 (colon cancer only). Deaths: 50,310 (colon and rectal cancers combined)...

    Read the General Information About Colon Cancer article > >

    The tumor extent is defined as:

    • M0 -no dissemination.
    • M1 -CSF-positive cytology only.
    • M2 -gross nodular seeding in cerebellar-cerebral subarachnoid space and/or lateral or third ventricle.
    • M3 -gross nodular seeding in spinal subarachnoid space.
    • M4 -extraneural metastasis.

    Postoperative degree of residual disease is designated as:

    • Gross-total resection/near-total resection-no or minimal (not measurable) evidence of residual disease after diagnosis.
    • Subtotal resection-residual disease after diagnosis; this is conventionally further subdivided into less than, greater than, or equal to 1.5 cm2 of measurable residual disease.
    • Biopsy-no tumor resection; only a sample of tumor tissue is removed.

    Since the 1990s, prospective studies have been performed using this staging system to separate patients into average-risk and high-risk medulloblastoma subgroups.[2,3,4]

    The presence of diffuse (>50% of the pathologic specimen) histologic anaplasia has been incorporated as an addition to staging systems. If diffuse anaplasia is found, patients with otherwise average-risk disease are up-staged to high-risk disease.

    Staging of CNS Primitive Neuroectodermal Tumors (PNETs)

    Patients with CNS PNETs are staged in a fashion similar to that used for children with medulloblastoma; however, the patients are not assigned to average-risk and high-risk subgroups for treatment purposes (refer to the Staging of Medulloblastoma section of this summary for more information).

    Staging of Medulloepithelioma and Ependymoblastoma

    Dissemination of both medulloepitheliomas and ependymoblastomas frequently occurs.[5,6] The tumors are staged in the same way as medulloblastoma; however, the patients are not assigned to average-risk and high-risk subgroups for treatment purposes (refer to the Staging of Medulloblastoma section of this summary for more information).

    1 | 2
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
     
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article